Marker Therapeutics Inc. has released a corporate presentation highlighting developments in its MAR-T cell therapy platform. The company's lead product, MT-601, is designed to target six tumor-specific antigens, offering broad tumor recognition for both blood and solid tumors. The APOLLO Phase 1 clinical trial for MT-601 has shown durable objective response rates in patients with lymphoma who relapsed after anti-CD19 CAR-T cell therapy or for whom CAR-T cell therapy is not an option. MT-601 is currently being studied in dose escalation and expansion cohorts, including disease-specific groups for diffuse large B cell lymphoma (DLBCL). The presentation also notes improvements in manufacturing processes and higher cell potency compared to earlier studies. Marker Therapeutics maintains a strong intellectual property position and has received over $30 million in non-dilutive funding from sources such as the NIH, FDA, and CPRIT. You can access the full presentation through the link below.